This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolff, R. A. Articles by Abbruzzese, J. L. Search for Related Content PubMed PubMed Citation Articles by Wolff, R. A. Articles by Abbruzzese, J. L.

Phase I Trial of Gemcitabine Combined with Radiation for the Treatment of Locally Advanced Pancreatic Adenocarcinoma¹

The Pancreatic Tumor Study Group, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030

Gemcitabine has modest activity in the treatment of advanced pancreatic cancer and is a potent radiosensitizer. We conducted a Phase I trial to determine the maximum tolerated dose of weekly gemcitabine delivered concurrently with radiation therapy for the treatment of locally advanced adenocarcinoma of the pancreatic head and to assess the treatment-related toxic effects associated with such a regimen. Eighteen patients with pathologically proven, locally advanced adenocarcinoma of the pancreatic head were enrolled in this study. Patients received seven weekly doses of gemcitabine with 3000 cGy of external beam radiation therapy delivered during the first 2 weeks of therapy. Six patients received gemcitabine at 350 mg/m²/week, nine at 400 mg/m²/week, and three at 500 mg/m²/week. Grade 3–4 hematological toxicity was observed in over half the patients treated. Nonhematological toxicities were significant and included fatigue, anorexia, nausea, vomiting, and dehydration. Forty-four % of the patients required admission to the hospital for management of nausea/vomiting and dehydration. The risk of hospitalization appeared to be dose-related; all of the three patients treated at 500 mg/m²/week required hospital admission during treatment. Seventeen patients were evaluated for response, and eight patients (47%) had evidence of a local anticancer effect. Four of these eight patients (24%) had a partial response to therapy. The median survival for the entire group was 6 months. The 1-year survival rate for patients with an objective response to therapy was 66%. The clinical responses observed in this group of patients suggest gemcitabine is a clinically relevant radiosensitizer in patients with pancreatic adenocarcinoma. However, the toxic effects are significant, suggesting that until dose and scheduling issues are explored further, concomitant administration of gemcitabine and radiation therapy should still be considered investigational.

This article has been cited by other articles:

				D. B. Evans, G. R. Varadhachary, C. H. Crane, C. C. Sun, J. E. Lee, P. W.T. Pisters, J.-N. Vauthey, H. Wang, K. R. Cleary, G. A. Staerkel, et al. Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head J. Clin. Oncol., July 20, 2008; 26(21): 3496 - 3502. [Abstract] [Full Text] [PDF]

				W. Small Jr, J. Berlin, G. M. Freedman, T. Lawrence, M. S. Talamonti, M. F. Mulcahy, A. B. Chakravarthy, A. A. Konski, M. M. Zalupski, P. A. Philip, et al. Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial J. Clin. Oncol., February 20, 2008; 26(6): 942 - 947. [Abstract] [Full Text] [PDF]

				S. P. Desai, E. Ben-Josef, D. P. Normolle, I. R. Francis, J. K. Greenson, D. M. Simeone, A. E. Chang, L. M. Colletti, T. S. Lawrence, and M. M. Zalupski Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer J. Clin. Oncol., October 10, 2007; 25(29): 4587 - 4592. [Abstract] [Full Text] [PDF]

				H. R. Cardenes, E. G. Chiorean, J. DeWitt, M. Schmidt, and P. Loehrer Locally advanced pancreatic cancer: current therapeutic approach. Oncologist, June 1, 2006; 11(6): 612 - 623. [Abstract] [Full Text] [PDF]

				M. S. Talamonti, W. Small Jr., M. F. Mulcahy, J. D. Wayne, V. Attaluri, L. M. Colletti, M. M. Zalupski, J. P. Hoffman, G. M. Freedman, T. J. Kinsella, et al. A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients With Potentially Resectable Pancreatic Carcinoma Ann. Surg. Oncol., February 1, 2006; 13(2): 150 - 158. [Abstract] [Full Text] [PDF]

				C. Blanquicett, M. W. Saif, D. J. Buchsbaum, M. Eloubeidi, S. M. Vickers, D. C. Chhieng, M. D. Carpenter, J. C. Sellers, S. Russo, R. B. Diasio, et al. Antitumor Efficacy of Capecitabine and Celecoxib in Irradiated and Lead-Shielded, Contralateral Human BxPC-3 Pancreatic Cancer Xenografts: Clinical Implications of Abscopal Effects Clin. Cancer Res., December 15, 2005; 11(24): 8773 - 8781. [Abstract] [Full Text] [PDF]

				P. M. Anderson, G. A. Wiseman, L. Erlandson, V. Rodriguez, B. Trotz, S. A. Dubansky, and K. Albritton Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma Clin. Cancer Res., October 1, 2005; 11(19): 6895 - 6900. [Abstract] [Full Text] [PDF]

				B. Pauwels, A. E.C. Korst, F. Lardon, and J. B. Vermorken Combined Modality Therapy of Gemcitabine and Radiation Oncologist, January 1, 2005; 10(1): 34 - 51. [Abstract] [Full Text] [PDF]

				M. T. Milano, D. J. Haraf, K. M. Stenson, M. E. Witt, C. Eng, B. B. Mittal, A. Argiris, H. Pelzer, M. F. Kozloff, and E. E. Vokes Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck Clin. Cancer Res., August 1, 2004; 10(15): 4922 - 4932. [Abstract] [Full Text] [PDF]

				E. Kent, H. Sandler, J. Montie, C. Lee, J. Herman, P. Esper, J. Fardig, and D. C. Smith Combined-Modality Therapy With Gemcitabine and Radiotherapy As a Bladder Preservation Strategy: Results of a Phase I Trial J. Clin. Oncol., July 1, 2004; 22(13): 2540 - 2545. [Abstract] [Full Text] [PDF]

				J. H. Muler, C. J. McGinn, D. Normolle, T. Lawrence, D. Brown, G. Hejna, and M. M. Zalupski Phase I Trial Using a Time-to-Event Continual Reassessment Strategy for Dose Escalation of Cisplatin Combined With Gemcitabine and Radiation Therapy in Pancreatic Cancer J. Clin. Oncol., January 15, 2004; 22(2): 238 - 243. [Abstract] [Full Text] [PDF]

				P. D. Jones, L.-P. de Lorimier, B. E. Kitchell, and J. M. Losonsky Gemcitabine as a Radiosensitizer for Nonresectable Feline Oral Squamous Cell Carcinoma J. Am. Anim. Hosp. Assoc., September 1, 2003; 39(5): 463 - 467. [Abstract] [Full Text] [PDF]

				P. W. T. Pisters, R. A. Wolff, N. A. Janjan, K. R. Cleary, C. Charnsangavej, C. N. Crane, R. Lenzi, J. Nicolas Vauthey, J. E. Lee, J. L. Abbruzzese, et al. Preoperative Paclitaxel and Concurrent Rapid-Fractionation Radiation for Resectable Pancreatic Adenocarcinoma: Toxicities, Histologic Response Rates, and Event-Free Outcome J. Clin. Oncol., May 15, 2002; 20(10): 2537 - 2544. [Abstract] [Full Text] [PDF]

				J. D. Wayne, E. K. Abdalla, R. A. Wolff, C. H. Crane, P. W.T. Pisters, and D. B. Evans Localized Adenocarcinoma of the Pancreas: The Rationale for Preoperative Chemoradiation Oncologist, February 1, 2002; 7(1): 34 - 45. [Abstract] [Full Text] [PDF]

				R. A. Wolff Neoadjuvant Chemoradiation for Localized Adenocarcinoma of the Pancreas: Great Logic, Grim Reality Ann. Surg. Oncol., December 1, 2001; 8(10): 747 - 748. [Full Text] [PDF]

				C. J. McGinn, M. M. Zalupski, I. Shureiqi, J. M. Robertson, F. E. Eckhauser, D. C. Smith, D. Brown, G. Hejna, M. Strawderman, D. Normolle, et al. Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Full-Dose Gemcitabine in Patients With Advanced Pancreatic Cancer J. Clin. Oncol., November 15, 2001; 19(22): 4202 - 4208. [Abstract] [Full Text]